Ascendis Pharma A/S (ASND)
210.16
+8.92
(+4.43%)
USD |
NASDAQ |
Dec 11, 16:00
211.00
+0.84
(+0.40%)
Pre-Market: 09:18
Ascendis Pharma Research and Development Expense (Quarterly): 76.00M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Evaxion AS | 2.158M |
| Novo Nordisk A/S | 2.410B |
| DBV Technologies SA | 26.82M |
| Cellectis SA | 19.34M |
| Biodexa Pharmaceuticals Plc | -- |